Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615
This examiner grants 29% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17675334 | MEDICAL DEVICE AND METHOD FOR MANUFACTURING SAME | Non-Final OA | TERUMO KABUSHIKI KAISHA |
| 18602424 | PROCESS FOR COLOURING A BASE COSMETIC COMPOSITION | Non-Final OA | L'Oreal |
| 18543756 | COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND AVOBENZONE | Non-Final OA | L'OREAL |
| 17740607 | COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 17595159 | COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18140510 | ANTIMICROBIAL CATHETER COATINGS WITH PASSIVE ANTIFUNGAL PROPERTIES | Final Rejection | Becton, Dickinson and Company |
| 17892436 | SURFACTANT FORMULATIONS FOR INHALATION | Non-Final OA | Merz Pharmaceuticals, LLC |
| 18009665 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEPSIS CONTAINING FUNCTIONALIZED TRANSITION METAL DICHALCOGENIDE | Non-Final OA | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS |
| 16963285 | FUNCTIONALLY GRADED POLYMER KNEE IMPLANT FOR ENHANCED FIXATION, WEAR RESISTANCE, AND MECHANICAL PROPERTIES AND THE FABRICATION THEREOF | Non-Final OA | Evonik Operations GmbH |
| 18010219 | BIODEGRADEABLE MULTI-CAVITY MICROPARTICLES AND THEIR USE IN TREATMENT | Final Rejection | OXFORD UNIVERSITY INNOVATION LIMITED |
| 18122661 | METHOD OF MANUFACTURING MICELLES FOR DRUG DELIVERY | Final Rejection | Wisconsin Alumni Research Foundation |
| 18822019 | Metal Oxide Compounds with Enhanced Reactivity | Non-Final OA | NANOIONIX, LLC |
| 18700528 | A personal care composition comprising vitamin K2 and hydroxystearic acid | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 17297836 | NON-ALUMINIUM ANTIPERSPIRANT COMPOSITIONS | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 17587667 | ANTIBODY-POLYMER CONJUGATES | Final Rejection | BOGAZICI UNIVERSITESI |
| 18755456 | METHODS AND FOODS INCLUDING SILVER COMPOUNDS TO PROTECT ANIMALS FROM PATHOGENIC BACTERIA AND DISEASE | Non-Final OA | SilverCeuticals Inc. |
| 18629598 | DEPOT ADMINISTRATION OF ILOPERIDONE | Non-Final OA | Vanda Pharmaceuticals Inc. |
| 17629639 | WATER BASED COMPOSITION | Final Rejection | Shiseido Company, Ltd. |
| 18700823 | Tooth Surface Treating Agent and Tooth Surface Treating Kit | Non-Final OA | Nishio Co. Ltd. |
| 14774102 | COMPOSITIONS OF ALKYLAMIDOTHIAZOLES AND UV-FILTER SUBSTANCES | Non-Final OA | BEIERSDORF AG |
| 18607759 | MODULATION OF SOLUBILITY, PALATABILITY, ABSORPTION, AND BIOAVAILABILITY OF MITRAGYNA SPECIOSA-DERIVED COMPOUNDS FOR ORAL AND BUCCAL DELIVERY | Final Rejection | Syncotrance, LLC |
| 18688918 | OPHTHALMIC FORMULATION FOR PREVENTING AND/OR TREATING CATARACTS BY EYE DROP ADMINISTRATION | Non-Final OA | CHENGDU RUIMU BIOPHARMACEUTICALS CO., LTD. |
| 18688439 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE | Non-Final OA | DONG-A ST CO., LTD. |
| 18686346 | NEW COATING OF IMPLANTS | Non-Final OA | Universität Münster |
| 16765775 | WATER-SOLUBLE POLYMER ADHESIVE LAYERS | Final Rejection | LTS LOHMANN THERAPIE-SYSTEME AG |
| 18442766 | PARTICLE-BASED MULTI-LAYER THERAPEUTIC DELIVERY DEVICE AND METHOD | Non-Final OA | Privo Technologies, Inc. |
| 18681804 | Antimicrobial, Antiviral and Antifungal Articles and Methods of Producing Such Articles | Non-Final OA | Cupron, Inc. |
| 18426299 | SUBCUTANEOUS BIODEGRADABLE NALTREXONE IMPLANT AND ACCOMPANYING BEHAVIORAL PROGRAM FOR WEIGHT LOSS IN A PATIENT | Final Rejection | Biocorrx |
| 17923945 | GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR | Non-Final OA | Spiral Therapeutics Inc. |
| 18418053 | INTRAVENOUS INFUSION DOSAGE FORM FOR PEMETREXED | Final Rejection | SUN PHARMACEUTICAL INDUSTRIES LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy